Ensign Peak Advisors
ORKA

Ensign Peak Advisors’s Oruka Therapeutics ORKA Stock Holding History

Ensign Peak Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44M Sell
67,668
-11,712
-15% -$780K 0.01% 520
2026
Q1 		$3.89M Buy
+79,380
New +$2.76M 0.01% 575
2025
Q1 		– Sell
-25,000
Closed -$485K – 1734
2024
Q4 		$485K Hold
25,000
– – ﹤0.01% 1605
2024
Q3 		$613K Buy
+25,000
New +$870K ﹤0.01% 1551

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ensign Peak Advisors's ORKA Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Oruka Therapeutics (ORKA) stake by 15% in Q2 2026, selling an estimated $780K and leaving 67,668 shares worth $6.44M. The position accounts for 0.01% of the portfolio, ranked #520.

Ensign Peak Advisors first reported a position in ORKA in Q3 2024 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Ensign Peak Advisors held 67,668 shares of Oruka Therapeutics worth $6.44M as of Q2 2026.
  • Ensign Peak Advisors sold 11,712 Oruka Therapeutics shares in Q2 2026, an estimated $780K.
  • Oruka Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #520 holding.
  • Ensign Peak Advisors first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.